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Ketamine (IM) Assisted Psychotherapy (KAP):
A Model for Informed Consent
Philip E. Wolfson
Center for Transformational Psychotherapy
San Francisco and San Anselmo, CA, USA
Informed consent is important for every medical intervention, and the unique nature of ketamine
assisted psychotherapy (KAP) calls for a particularly thoughtful and detailed informed consent
document. The following is an informed consent form developed for the author’s use in his own private
practice. No representations are made concerning its adequacy or appropriateness for use by other
practitioners, or in any other contexts; author, editors, and publisher disclaim liability for any use of or
reliance on this document. However, as a document created by a psychiatrist with experience in KAP,
this form may serve to illustrate the range of issues that an informed consent document might address.

Ketamine (IM) Assisted Psychotherapy
Informed Consent Form
What is Ketamine?

K

etamine is now a validated “off-label” treatment for various chronic “treatment-resistant”
mental illnesses. Ketamine is a Schedule III medication that has long been used safely
as an anesthetic agent and now, at times, effectively as treatment for depression, alcoholism,
substance dependencies, PTSD and other psychiatric diagnoses.
How Does It Work?

T

he current, most probable, understanding of ketamine’s mode of action is as an NMDA
antagonist working through the glutamate neurotransmitter system. It is classified as a
dissociative anesthetic. At the dosage level administered to you, you will most likely experience
analgesic, anxiolytic, antidepressant, and psychedelic effects. Ketamine also may bring about
“transpersonal,” “mystical,” or “out-of-body” experiences that may also serve to facilitate a shift
in your perspective and emotional state.
Monitoring

I

t is essential that you be followed very closely during and after your treatment. This will
include blood pressure and pulse measurements, some psychological measurements before
and after your session, close supervision and support during your treatment session with your
physician/psychiatrist/psychotherapist, and follow-up telephone and in-person contact with
your treatment team.
You will be entering a psychotherapy program that will prepare you for your ketamine
session(s) and assist you in integrating your experience(s) afterwards. This program emphasizes
the possibilities for change and the seriousness of your and our effort to assist you.
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How Long Will It Take Before I Might See Beneficial Effects?

Y

ou may experience important changes in personality, mood, and cognition during treatment,
in the immediate aftermath, and in the days and weeks that follow. Some experiences may
be temporarily disturbing to you. The ketamine experience itself is designed to enable your
own healing wisdom to be accessed and beneficial to you. The psychotherapeutic support you
will receive will aid you in making your experience(s) valuable and understandable to you.
Some experiences may be temporarily disturbing, but the integration process may greatly help
you move to clarity and understanding.
Why Ketamine (IM) Assisted Psychotherapy?

T

he purpose of KAP is to create a non-ordinary (“altered”) state of consciousness in
order to facilitate profound transpersonal (“transcendental,” “mystical,” “spiritual,”
“religious”) peak experiences that may be beneficial in resolving your existential problems,
accelerating your psycho-spiritual growth and lead you to a deep personal transformation and
optimization of your lifestyle. Such change is best facilitated within a structured supportive
psychotherapeutic milieu in connection with therapists who have a view of your issues, hopes,
desires, and struggles. As a byproduct of your experience you may well feel improvement in
your emotional state and reduction in symptoms that bother you such as depression, anxiety,
and post-traumatic manifestations. You may notice that you are a bit different after a ketamine
experience and that difference may well be liberating and allow for new mindfulness and new
behavior. It is frequently the case that a ketamine experience may promote happiness, empathy,
loving-kindness to self and others, and a sense of greater self-acceptance and peacefulness.
Your experience will be unique to you. If you and we decide to have additional sessions
using ketamine, each of your sessions will be different. All such journeys are adventures that
cannot be programmed. They evolve from your own being in relation to this substance. While
it is best to form an intention for your journey, you may or may not be able to hold onto that.
Indeed, no holding on is best and the journey will flow whether or not you hold on and resist,
or follow the path that unfolds and relax into it. Holding on is the main source of anxiety
in this and other related journeys. A ketamine session can be light, dark, or both. There will
be concepts, visions, encounters, and you may well deal with your own death, mortality, and
immortality. Not everyone enjoys the journey, but everyone comes through it—and generally
with a measure of positive change and a sense of having had a profound experience that may
be life changing indeed.
Eligibility for KAP

T

his consent form contains information about the use of sub-anesthetic dosages of ketamine
for psychiatric purposes including depression. Ketamine was approved by the FDA for
use as an anesthetic agent several decades ago. Ketamine has an extensive record of safety and
has been used at much higher doses for surgical anesthesia, without respiratory depression. The
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administration of ketamine in lower, sub-anesthetic doses to treat pain, depression, or other
psychiatric diagnoses is a newer, off-label use of ketamine. Psychiatric use of ketamine has
become relatively widespread in recent years, has been studied and promoted by researchers at
the National Institute of Mental Health, and has had publicity as the newest anti-depressant
with its own novel pharmacological mechanism of action. Ketamine has been administered
by intravenous, intramuscular (IM), and intranasal routes. Often, it has been used after other
treatment approaches have been unsuccessful.
Once you indicate that you have understood the benefits and risks of this treatment,
you will be asked to sign this form in order to participate in this treatment. You will be given
a signed copy of this form to keep for your own records. This process is known as giving
informed consent.
By signing this document, you indicate that you understand the information provided
and that you give your consent to the medical procedure to be performed during your
participation in ketamine treatment. Please read this consent form carefully, and feel free to
ask questions about any of the information in it.
Participation in Ketamine Assisted Psychotherapy

B

efore participating in ketamine treatment, you will be carefully interviewed to determine
whether you are eligible for ketamine therapy, including a medical history, a physical exam
if deemed necessary, review of your medical/psychiatric records, a psychiatric history and
administration of brief psychological tests to assess your state of mind.
• Pregnant women and nursing mothers are not eligible because of
potential effects on the fetus, or nursing child. The effects of ketamine
on pregnancy and the fetus are undetermined, and therefore, it is
advisable to protect against pregnancy while exposing yourself to
ketamine or in the immediate aftermath of its use.
• Untreated hypertension is a contra-indication to ketamine use as
the substance causes a rise in blood pressure. Similarly, a history of
heart disease may make you ineligible to participate.
• Information on ketamine’s interaction with other medicines is only
partially available and it will be assessed as to your eligibility for
KAP.
• Ketamine should not be taken if you have hyperthyroidism. There
have also been reports of some decrease in immune function in
patients receiving surgical doses of ketamine.
Ketamine has an extensive record of safety and has been used at much higher doses for
surgical anesthesia, without respiratory depression, making it an ideal anesthetic agent.
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Overview of Ketamine (IM) Assisted Therapy—KAP

D

uring the Ketamine administration session, you will be asked to make two (2) agreements
with the therapist(s) to ensure your safety and well-being:
• You agree to follow any direct instructions given to you by the
therapist(s) until it is determined that the session is over, and
• You agree to remain at the location of the session until the therapist(s)
decides you are ready to leave.

The length of ketamine sessions varies from person-to-person and from experienceto-experience. You will be mostly internally focused for the first 45 minutes to one-hourand-a-half following IM administration of ketamine. You will continue to remain under
ketamine’s influence at a lesser level for at least one hour. Under my care, ketamine will be
given as an intramuscular injection into the shoulder or buttocks at doses of 50 mg or 100 mg
(130mg maximally). The choice of dose will depend on prior exposure to ketamine and other
psychedelics. Naïve subjects will receive a lower dose in the initial session. It is always better
to start with a lower dose to reduce anxiety and become familiar with what a substance may
produce in you. There is always an opportunity to make a choice for a larger dose at a future
date—if appropriate. It is more difficult to correct a bad experience because of too high an
initial dose and the anxiety it may engender. Individuals experienced with psychedelics may
receive a higher initial dose. Ketamine IM creates an unusual experience of formlessness and
a dissolving of boundaries and has novel effects on the mind. Therefore, it is much better to
have an initial learning experience for familiarization with ketamine and its effects on you.
Preparation for a ketamine session requires assessment by your therapist of your
readiness and a sense of connection between you and your therapist. We are engaging in
a therapeutic endeavor to benefit you and those who are affected by you. Together, we are
creating a therapeutic state that is based on rapport and trust (set) in a safe and conducive
setting. That will require prior sessions to your use of the drug. After ketamine IM use, you
will have follow-up sessions that focus on integration of your experience and may lead to
further sessions, if you so wish, and if that is in accord with your therapist’s view of your
treatment.
You may ask the therapist(s) any questions you may have concerning the procedure or
effects of ketamine at any time. Your consent to receive ketamine may be withdrawn by you,
and you may discontinue your participation at any time up until the actual injection has been
given.
Potential Risks of Ketamine (IM) Assisted Therapy

Y

ou will be asked to lie still during the ketamine administration because your sense of
balance and coordination will be adversely affected until the drug’s effect has worn off—
generally two and up to four hours after the injection. Other possibilities for adverse effects
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include blurred and uncomfortable vision (you are advised to keep your eyes closed until the
main effects have worn off), slurred speech, mental confusion, excitability, diminished ability
to see things that are actually present, diminished ability to hear or to feel objects acccurately
including one’s own body, anxiety, nausea and vomiting. Visual, tactile and auditory processing
are affected by the drug. Familiar music may appear quite different to you, even unrecognizable.
Synesthesia, a mingling of the senses, may occur. Ordinary sense of time may morph into time
dilation.
Because of the risk of nausea and vomiting, please refrain from eating and
drinking for at least the 6 hours preceding the session. On the day of treatment,
if you eat prior to the 6-hour fasting period, eat lightly. Hydrate well prior to the
6-hour fasting period.
If you are unduly nauseated, you may be offered an anti-nausea medication—
odansetron—either orally or by injection.
Ketamine generally causes a significant increase in blood pressure but ususally
not pulse rate. If blood pressure monitoring reveals that your blood pressure is too
high, you may be offered clonidine to remedy this.
Agitation may occur during the course of a ketamine session. If your agitation
is severe, you may be offered lorazepam orally or by injection to help you relax.
The administration of ketamine may also cause the following adverse reactions:
tachycardia (elevation of pulse), diplopia (double vision), nystagmus (rapid eye movements),
elevation of intraocular pressure (feeling of pressure in the eyes), and anorexia (loss of
appetite). The above reactions occurred after rapid intravenous administration of ketamine or
intramuscular administration of high doses of ketamine (in a range of greater than 5 mg/kg
used for a surgical anesthesia. The dose to be used in this sub-anesthetic ketamine therapy is
much lower (2 mg/kg or less).
Driving an automobile or engaging in hazardous activities should not be undertaken
for 6 hours after treatment with ketamine and definitively until all effects have stopped if for
any reason they continue longer.
In terms of psychological risk, ketamine has been shown to worsen certain psychotic
symptoms in people who suffer from Schizophrenia or other serious Mental Disorders. It may
also worsen underlying psychological problems in people with severe Personality Disorders. If
you have been or are presently diagnosed with similar severe Mental Disorders, you may not
be a candidate for KAP.
During the experience itself, some people have reported frightening, unusual experiences.
These frightening experiences, however, may be of paramount value to your transition to recovery
from the suffering that brought you to your KAP work. You will receive psyhotherapeutic help
and ongoing guidance from your therapist.
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Potential for Ketamine Abuse and Physical Dependence

K

etamine belongs to the same group of chemicals as Phencyclidine (Sernyl, PCP, “Angel
dust”). This group of chemical compounds is known chemically as Arylcyclohexylamines
and is classified as Hallucinogens (“Psychedelics”). Ketamine is a controlled substance and is
subject to Schedule III rules under the Controlled Substance Act of 1970. Medical evidence
regarding the issue of drug abuse and dependence suggests that ketamine’s abuse potential is
equivalent to that of phencyclidine and other hallucinogenic substances.
Phencyclidine and other hallucinogenic compounds do not meet criteria for chemical
dependence, since they do not cause tolerance and withdrawal symptoms. However, “cravings”
have been reported by individuals with a history of heavy use of “psychedelic” drugs. In
addition, ketamine can have effects on mood (feelings), cognition (thinking), and perception
(imagery) that may make some people want to use it repeatedly. Therefore, ketamine should
never be used except under the direct supervision of a licensed physician.
Alternative Procedures and Possibilities

N

o other procedure is available in medicine that produces ketamine’s effects. Major
Depression (MDD) and Bipolar Disorders are usually treated with anti-depressant
medications, tranquilizers, mood stabilizers, and psychotherapy. Electroconvulsive therapy
(ECT), and the recently introduced Transcranial Magnetic Stimulation (TMS), are also in use
for treatment-resistant-depression. Ketamine has also been used in the treatment of addictions
and alcoholism as part of comprehensive and usually residential treatment programs, primarily
abroad.
Confidentiality

Y

our privacy and all therapy records will be kept confidential. They will be maintained with
the same precautions as ordinary medical records. To allow others access to your records,
you will have to provide a signed release form. The results of this ketamine therapy may be
published in clinical literature. Published reports will not include your name or any other
information that would identify you.
Voluntary Nature of Participation

P

lease be aware that the Food and Drug Administration (FDA) has not yet established the
appropriateness of Ketamine Assisted Psychotherapy, and its use is considered off-label, the
only official “indication” for use of ketamine being anesthesia. Your awareness of this situation
is key to understanding any liability associated with your use of ketamine. Your informed
consent indicates you are aware of this situation.
Ketamine is a new psychiatric treatment—the primary studies have been with depression,
bipolar disorders, and alcoholism. It is not yet a mainstream treatment, though there are now
many studies that demonstrate that it may be an effective treatment. That effect generally
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occurs with more than one treatment and is most robust when part of an overall treatment
program. It may not permanently relieve depression. If your depressive symptoms respond
to Ketamine Assisted Psychotherapy, you may still elect to be treated with medications and
ongoing psychotherapy to try to reduce the possibility of relapse. Over time, you may also need
additional ketamine treatments or other therapies to maintain your remission.
Your decision to undertake Ketamine Assisted Psychotherapy is completely voluntary.
Before you make your decision about participating in KAP, you may ask and will be encouraged
to ask any questions you may have about the process.
Withdrawal From KAP is Always Your Right!!!

E

ven after agreeing to undertake Ketamine Assisted Psychotherapy, you may decide to
withdraw from treatment at any time.
REMEMBER:
You are to have no food or drink 6 hours prior to the Ketamine session.
You will need to have someone drive you home from the sessions, and you must
not engage in any driving or hazardous activity for at least 6 hours or more—
depending on the continued presence of effects after the session has concluded.
Informed Consent

By signing this form I agree that:
1. I have fully read this informed consent form describing Ketamine Assisted Psychotherapy.
2. I have had the opportunity to raise questions and have received satisfactory answers.
3. I fully understand that the ketamine session(s) can result in a profound change in mental
state and may result in unusual psychological and physiological effects.
4. I understand that I am to have no food or drink for 6 hours prior to my Ketamine
session.
5. I understand that I need to make arrangements to have someone drive me home from
the Ketamine sessions.
6. I agree that I will not engage in any driving or hazardous activity for at least 6 hours or
longer after my session has concluded, and that I will not engage in any such activities
until the effects of the Ketamine-induced state are no longer present.
7. I give my consent to the use of lorazepam if deemed necessary for agitation, to odansetron
for nausea, and for clonidine for high blood pressure.
5. I have been given a signed copy of this informed consent form, which is mine to keep.
6. I understand the risks and benefits, and I freely give my consent to participate in KAP
as outlined in this form, and under the conditions indicated in it.
7. I understand that I may withdraw from KAP at any time, up until the actual injection
has been given.
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Signature
Date
Printed Name
Physician / Therapist Statement
I have carefully explained the nature of Ketamine Assisted Psychotherapy to
. I hereby certify that to the best of my knowledge, the
individual signing this consent form understands the nature, conditions, risks and potential
benefits involved in participating in KAP.
A medical problem or language or educational barrier has not precluded a clear understanding
of the subject’s involvement in KAP.
Signature of Physician / Therapist
Date
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